Cynata Therapeutics

Gain a direct line to Cynata Therapeutics leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact Us

Pre-Clinical Development

Clinical Development

Products & Pipeline

Scientific Publications

Intellectual Property

Cymerus™ Platform

Our technology

Board of Directors

Management team

About us

Company FAQs

Corporate Governance

Share Price

Investor FAQs

Analyst Research

Financial Reports

Right to Receive Documents

Investor Presentations

Announcements

Investors

Updates

Home

Frank Ruhl Libre

upload.jpg

Listen to podcast

Cynata CEO Dr Kilian Kelly recently joined Karen Jagoda on the Empowered Patient Podcast to discuss "Scalable MSC Platform Enabling Next Wave of Stem Cell Therapies."

In this episode, Dr Kelly explores how our proprietary Cymerus™ technology is revolutionising mesenchymal stem cell (MSC) manufacturing to overcome the industry's biggest challenge: consistency and scalability.

Key points:
- How single-source manufacturing eliminates donor variability that has plagued stem cells to date
- Our 'off-the-shelf' approach with five-year shelf life enabling global distribution
- Clinical progress across multiple indications (graft-versus-host disease showing 60% two-year survival vs 20% standard of care)
- Phase 3 osteoarthritis trial results approaching, potentially the first disease-modifying treatment
- Revolutionary topical wound dressing showing 85% wound reduction vs 40% standard care

Dr Kelly positions MSC therapies at an inflection point: "We are at the start of the next uptick in the cycle, and I would be very surprised if we don't have a lot of MSC-based therapies coming to market in the next five to 10 years."

Scalable MSC platform enabling next wave of stem cell therapies with Dr. Kilian Kelly Cynata Therapeutics